Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)

Inclusion Criteria:

* Confirmed diagnosis of locally advanced unresectable or metastatic NSCLC;
* Aged at least 18 years at first diagnosis of locally advanced/metastatic NSCLC;
* Lab-confirmed EGFR mutation;
* Received a first- or second-generation EGFR TKI as first-line treatment for advanced/metastatic disease;
* First-line EGFR TKI (afatinib, gefitinib, erlotinib) initiated between January 1, 2015 and June 30, 2018;
* Patients may be alive or deceased at the time of medical record review.

Exclusion Criteria:

* Patients enrolled at any time in an interventional clinical trial for an experimental treatment related to EGFR-mutated NSCLC;
* Patients receiving any systemic therapy for locally advanced or metastatic NSCLC prior to first-line EGFR TKI treatment in the locally advanced/metastatic setting;
* Missing or unknown data on any of the following key study dates:

  * Date of initial NSCLC diagnosis;
  * Date of first diagnosis of or progression to advanced/metastatic NSCLC;
  * Date of first-line EGFR TKI initiation for advanced/metastatic disease;
  * Date of death or last available follow-up.